Login here to update your profile  
My Profile

Kevin Nash, Ph.D.
Assistant Professor, Dept. of Molecular Pharmacology and Physiology, College of Medicine

Primary Department: COLLEGE OF MEDICINE MOLECULAR PHARMACOLOGY & PHYSIOLOGY

Assistant Professor
COLLEGE OF MEDICINE MOLECULAR PHARMACOLOGY & PHYSIOLOGY

profile Image
Contacts
Email: knash@health.usf.edu
Phone: (813) 974-3788
Office: ALZ, 421
Mailing address 12901 Bruce B. Downs Blvd. MDC 8
Tampa, FL 33612
 
Education
  • Ph.D. , Biochemistry, University of Queensland, Queensland, Australia - 1996.
  • PHD, Biochemistry, University Of Queensland, Australia - 1996.
  • B.S., Biochemistry and Microbiology, University of Queensland, Queensland, Australia - 1991.
  •  
    Interdisciplinary & Emerging Signature Programs
    Neurodegenerative Disease, Neuroscience.
     
    Research Summary

    My research focus is now targeted towards using recombinant Adeno-associated virus (rAAV) to study of neurological disorders. We have examined the use of rAAV to over express proteases including neprilysin (NEP), insulin degrading enzyme (IDE; also known as insulysin) and endothelin converting enzyme (ECE) to remove beta-amyloid which is deposited in Alzhiemer disease. To facilitate the diffusion of the protease enzymes to the amyloid plaques, we have engineered the proteins with a signal peptide triggering secretion. We have successfully observed a reduction in amyloid plaques with both NEP and ECE in APP+PS1 transgenic Alzheimer mice models. We are also using rAAV to study an inflammatory molecule known as Fractalkine. Fractalkine reduces the pro-inflammatory response that is observed in many neurological diseases. We are examining whether this reduction in inflammation would be beneficial in Alzheimer and Parkinson’s diseases.

     


    Selected Publications
  • Selenica ML, Benner L, Housley SB, Manchec B, Lee DC, Nash KR, Kalin J, Bergman JA, Kozikowski A, Gordon MN, Morgan D. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimer's research & therapy. 6(1) : 12, 2014.
  • Nash KR, Moran P, Finneran DJ, Hudson C, Robinson J, Morgan D, Bickford PC. Fractalkine Over Expression Suppresses α-Synuclein-mediated Neurodegeneration. Molecular therapy : the journal of the American Society of Gene Therapy. : , 2014.
  • Nash KR, Lee DC, Hunt JB, Morganti JM, Selenica ML, Moran P, Reid P, Brownlow M, Guang-Yu Yang C, Savalia M, Gemma C, Bickford PC, Gordon MN, Morgan D. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiology of aging. 34(6) : 1540-8, 2013.
  • Lee DC, Ruiz CR, Lebson L, Selenica ML, Rizer J, Hunt JB, Rojiani R, Reid P, Kammath S, Nash K, Dickey CA, Gordon M, Morgan D. Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiology of aging. 34(6) : 1610-20, 2013.
  • Carty N, Nash KR, Brownlow M, Cruite D, Wilcock D, Selenica ML, Lee DC, Gordon MN, Morgan D. Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. PloS one. 8(3) : e59626, 2013.
  • Selenica ML, Alvarez JA, Nash KR, Lee DC, Cao C, Lin X, Reid P, Mouton PR, Morgan D, Gordon MN. Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. Journal of neuroinflammation. 10: 86, 2013.
  • Li Q, Lebson L, Lee DC, Nash K, Grimm J, Rosenthal A, Selenica ML, Morgan D, Gordon MN. Chronological age impacts immunotherapy and monocyte uptake independent of amyloid load. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 7(1) : 202-14, 2012.
  • Nash KR, Cardenas-Aguayo MC, Berg MJ, Marks N. Transduction of E13 murine neural precursor cells by non-immunogenic recombinant adeno-associated viruses induces major changes in neuronal phenotype. Neuroscience. 210: 82-98, 2012.
  • Daily JL, Nash K, Jinwal U, Golde T, Rogers J, Peters MM, Burdine RD, Dickey C, Banko JL, Weeber EJ. Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome. PloS one. 6(12) : e27221, 2011.
  • Choi YK, Nash K, Byrne BJ, Muzyczka N, Song S. The effect of DNA-dependent protein kinase on adeno-associated virus replication. PloS one. 5(12) : e15073, 2010.
  • Galleguillos D, Fuentealba JA, Gómez LM, Saver M, Gómez A, Nash K, Burger C, Gysling K, Andrés ME. Nurr1 regulates RET expression in dopamine neurons of adult rat midbrain. Journal of neurochemistry. 114(4) : 1158-67, 2010.
  • Carty N, Lee D, Dickey C, Ceballos-Diaz C, Jansen-West K, Golde TE, Gordon MN, Morgan D, Nash K. Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. Journal of neuroscience methods. 194(1) : 144-53, 2010.
  • Lebson L, Nash K, Kamath S, Herber D, Carty N, Lee DC, Li Q, Szekeres K, Jinwal U, Koren J, Dickey CA, Gottschall PE, Morgan D, Gordon MN. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 30(29) : 9651-8, 2010.
  • Gorbatyuk OS, Li S, Nash K, Gorbatyuk M, Lewin AS, Sullivan LF, Mandel RJ, Chen W, Meyers C, Manfredsson FP, Muzyczka N. In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Molecular therapy : the journal of the American Society of Gene Therapy. 18(8) : 1450-7, 2010.
  • Nash K, Chen W, Salganik M, Muzyczka N. Identification of cellular proteins that interact with the adeno-associated virus rep protein. Journal of virology. 83(1) : 454-69, 2009.
  • Levy HC, Bowman VD, Govindasamy L, McKenna R, Nash K, Warrington K, Chen W, Muzyczka N, Yan X, Baker TS, Agbandje-McKenna M. Heparin binding induces conformational changes in Adeno-associated virus serotype 2. Journal of structural biology. 165(3) : 146-56, 2009.
  • Carty NC, Nash K, Lee D, Mercer M, Gottschall PE, Meyers C, Muzyczka N, Gordon MN, Morgan D. Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice. Molecular therapy : the journal of the American Society of Gene Therapy. 16(9) : 1580-6, 2008.
  • Nash K, Chen W, Muzyczka N. Complete in vitro reconstitution of adeno-associated virus DNA replication requires the minichromosome maintenance complex proteins. Journal of virology. 82(3) : 1458-64, 2008.
  • Nash K, Chen W, McDonald WF, Zhou X, Muzyczka N. Purification of host cell enzymes involved in adeno-associated virus DNA replication. Journal of virology. 81(11) : 5777-87, 2007.
  • Mandel RJ, Manfredsson FP, Foust KD, Rising A, Reimsnider S, Nash K, Burger C. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Molecular therapy : the journal of the American Society of Gene Therapy. 13(3) : 463-83, 2006.
  • Kohlbrenner E, Aslanidi G, Nash K, Shklyaev S, Campbell-Thompson M, Byrne BJ, Snyder RO, Muzyczka N, Warrington KH, Zolotukhin S. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Molecular therapy : the journal of the American Society of Gene Therapy. 12(6) : 1217-25, 2005.
  • Burger C, Nash K, Mandel RJ. Recombinant adeno-associated viral vectors in the nervous system. Human gene therapy. 16(7) : 781-91, 2005.
  • Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Molecular therapy : the journal of the American Society of Gene Therapy. 12(4) : 618-33, 2005.
  • Valizadeh M, Schenk G, Nash K, Oddie GW, Guddat LW, Hume DA, de Jersey J, Burke TR, Hamilton S. Phosphotyrosyl peptides and analogues as substrates and inhibitors of purple acid phosphatases. Archives of biochemistry and biophysics. 424(2) : 154-62, 2004.
  • Dunn BM, Pennington MW, Frase DC, Nash K. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem. Biopolymers. 51(1) : 69-77, 1999.
  • Marshall K, Nash K, Haussman G, Cassady I, Hume D, de Jersey J, Hamilton S. Recombinant human and mouse purple acid phosphatases: expression and characterization. Archives of biochemistry and biophysics. 345(2) : 230-6, 1997.
  • Nash K, Feldmuller M, de Jersey J, Alewood P, Hamilton S. Continuous and discontinuous assays for phosphotyrosyl protein phosphatase activity using phosphotyrosyl peptide substrates. Analytical biochemistry. 213(2) : 303-9, 1993.

  • Positions Held
  • Research Assistant Professor (Powell Centre for Gene Therapy, University of Florida 2002 - 2007)


  • Memberships
  • The American Association for the Advancement of Science (Member, 2008 - Present)
  • American Society of Gene Therapy (Member, 2008 - Present)
  • Society for Neuroscience (Member, 2008 - Present)


  • Patents & Licensing
  • Pseudotyping of recombinant AAV verions (Snyder et al.) Patent pending (US Application No. 60/385,864 - 2008)


  • Profile last modified on 08/23/2013